Daklinza (daclatasvir) / BMS  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daklinza (daclatasvir) / BMS
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Checkmark VHC 2015
Sep 2015 - Sep 2015: VHC 2015
Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Checkmark VHC 2014
More
No Longer Available
N/A
Europe
Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT02161939: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Checkmark
Jul 2014 - Jul 2014: 
No Longer Available
N/A
US
Daclatasvir (BMS-790052), Sofosbuvir
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT04122066: the Pulmonary Safety of Antihepatitis C Treatment

Not yet recruiting
N/A
50
NA
sofosbuvir \daclatsvir, Sovaldi\Daklinza
Assiut University
Hepatitis C
12/22
12/23

Download Options